Javascript must be enabled to continue!
Recombinant Human Erythropoietin Inhibits the Cutaneous Vasodilatation Induced by Acetylcholine
View through CrossRef
We investigated by means of telethermography the contractile response of cutaneous vessels to recombinant erythropoietin (rHuEPO) and the effects of this hormone on the vasodilatation induced by either acetylcholine, which is endothelium-dependent, and nitroprusside, which is endothelium-indepen-dent. Experiments were carried out in 12 healthy volunteers. Graded doses of rHuEPO (25, 50, 500U/min), acetylcholine (7.5 and 15µg/min), sodium nitroprusside (3 and 10 µg/min), and saline solution (sodium chloride 0.9%) were infused in the dorsal pedal artery of the lower limb. rHuEPO reduced the cutaneous temperature in a dose-dependent manner compared to the saline solution, thus suggesting that the hormone causes vasoconstriction. In contrast graded doses of acetylcholine and nitroprusside provoked vasodilatation: in fact both increased the cutaneous temperature compared to controls in a dose-dependent manner. The infusion of vasoconstrictive doses of rHuEPO in association with acetylcholine (15 µg/min) reverted the increase in the cutaneous temperature induced by the endothelium-dependent vasodilator. In contrast rHuEPO administered in combination with nitroprusside failed to block the vasodilatation induced by the endothelium-independent vasodilator. Therefore our data suggest that rHuEPO exerts an indirect vasoconstrictive effect and that acetylcholine-induced vasodilatation, which is endothelium-dependent, is blunted by the vasoconstrictive activity of rHuEPO, thus demonstrating that the hormone may impair the synthesis of endothelial nitric oxide.
Title: Recombinant Human Erythropoietin Inhibits the Cutaneous Vasodilatation Induced by Acetylcholine
Description:
We investigated by means of telethermography the contractile response of cutaneous vessels to recombinant erythropoietin (rHuEPO) and the effects of this hormone on the vasodilatation induced by either acetylcholine, which is endothelium-dependent, and nitroprusside, which is endothelium-indepen-dent.
Experiments were carried out in 12 healthy volunteers.
Graded doses of rHuEPO (25, 50, 500U/min), acetylcholine (7.
5 and 15µg/min), sodium nitroprusside (3 and 10 µg/min), and saline solution (sodium chloride 0.
9%) were infused in the dorsal pedal artery of the lower limb.
rHuEPO reduced the cutaneous temperature in a dose-dependent manner compared to the saline solution, thus suggesting that the hormone causes vasoconstriction.
In contrast graded doses of acetylcholine and nitroprusside provoked vasodilatation: in fact both increased the cutaneous temperature compared to controls in a dose-dependent manner.
The infusion of vasoconstrictive doses of rHuEPO in association with acetylcholine (15 µg/min) reverted the increase in the cutaneous temperature induced by the endothelium-dependent vasodilator.
In contrast rHuEPO administered in combination with nitroprusside failed to block the vasodilatation induced by the endothelium-independent vasodilator.
Therefore our data suggest that rHuEPO exerts an indirect vasoconstrictive effect and that acetylcholine-induced vasodilatation, which is endothelium-dependent, is blunted by the vasoconstrictive activity of rHuEPO, thus demonstrating that the hormone may impair the synthesis of endothelial nitric oxide.
Related Results
Survival of recombinant erythropoietin in the circulation: the role of carbohydrates
Survival of recombinant erythropoietin in the circulation: the role of carbohydrates
Recombinant human erythropoietin produced in transfected Chinese hamster ovary cells is glycosylated much the same way as the erythropoietin present in human urine. To determine th...
Survival of recombinant erythropoietin in the circulation: the role of carbohydrates
Survival of recombinant erythropoietin in the circulation: the role of carbohydrates
Abstract
Recombinant human erythropoietin produced in transfected Chinese hamster ovary cells is glycosylated much the same way as the erythropoietin present in huma...
Human Recombinant Erythropoietin in Asphyxia Neonatorum: Pilot Trial
Human Recombinant Erythropoietin in Asphyxia Neonatorum: Pilot Trial
OBJECTIVE:
The goal was to examine biochemical, neurophysiologic, anatomic, and clinical changes associated with erythropoietin administration to neonates with ...
Hemostasis with Erythropoietin in Massive, Uncontrollable, Diffuse GI Bleeding.
Hemostasis with Erythropoietin in Massive, Uncontrollable, Diffuse GI Bleeding.
Abstract
Purpose: Erythropoietin currently used as a hemopoietic agent, has remarkable hemostatic activity which can be lifesaving in diffuse, uncontrollable bleedin...
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Background
Cutaneous involvement is very common in systemic lupus erythematosus. We describe the prevalence and spectrum of lupus-specific (cutaneous lupus eryt...
Use of Erythropoietin and Fibrin Glue Mixture for Peripheral Nerve Repair
Use of Erythropoietin and Fibrin Glue Mixture for Peripheral Nerve Repair
Background:
Erythropoietin has neuroregenerative effects. Fibrin glue may be used for nerve repair and controlled release of substances. In this study, the authors inve...
Orally administrated Juzen‐taiho‐to/TJ‐48 ameliorates erythropoietin (rHuEPO)‐resistant anemia in patients on hemodialysis
Orally administrated Juzen‐taiho‐to/TJ‐48 ameliorates erythropoietin (rHuEPO)‐resistant anemia in patients on hemodialysis
AbstractMaintenance of the red blood cell volume is a fundamental aspect of ensuring oxygen supply to the tissue. Recombinant human erythropoietin (rHuEPO) was approved for marketi...
Histaminergic Modulation of Hippocampal Acetylcholine Release In Vivo
Histaminergic Modulation of Hippocampal Acetylcholine Release In Vivo
Abstract:In order to elucidate the modulatory role of the histaminergic neural system in the cholinergic neural system, the acetylcholine release from the CA1‐CA3 region in the hip...

